文献速递分子诊断临床血液与体液

新型扩增子NGS检测评估转移性结直肠癌患者循环肿瘤DNA的分析与临床验证

Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
PubMed 文献 · Clin Chem Lab Med · 2019-01-01

该研究评估了基于串联体纠错策略的扩增子NGS检测Firefly对mCRC患者血浆cfDNA中KRAS/NRAS/BRAF/PIK3CA突变的分析与临床性能,并与组织ARMS-PCR对比。结果显示Firefly在20 ng cfDNA、等位基因频率0.2%时检出率达98.89%,血浆与组织总体一致性80.11%,治疗前队列一致性93.33%。

要点

  • Firefly检测血浆cfDNA突变与组织ARMS结果高度一致,可作为mCRC突变分析补充。
  • 治疗前队列中KRAS/NRAS/BRAF/PIK3CA的PPA为100%、NPA为99.60%。
  • Firefly在20 ng cfDNA、AF 0.2%时检出率达98.89%,敏感性和特异性优越。

核心结论

  • Firefly检测血浆cfDNA与匹配肿瘤组织突变状态高度一致,可作为mCRC患者突变谱分析的可行补充,有望常规用于临床。

研究设计与样本

  • 研究采用Firefly扩增子NGS检测KRAS/NRAS/BRAF/PIK3CA,评估cfDNA参考标准品及184例mCRC患者cfDNA样本,并与匹配组织ARMS-PCR结果对比。

主要发现

  • Firefly在20 ng cfDNA、等位基因频率0.2%时检出率达98.89%,敏感性和特异性优越。
  • 血浆cfDNA NGS阳性率为40.76%,FFPE组织ARMS阳性率为48.37%,两平台总体一致性为80.11%。
  • 治疗前队列基于17个共同外显子的一致性为93.33%,KRAS/NRAS/BRAF/PIK3CA的PPA为100%、NPA为99.60%。

关键数值与推荐

  • Firefly检测20 ng cfDNA在AF 0.2%时检出率为98.89%。
  • 血浆NGS与组织ARMS总体一致性为80.11%,治疗前队列一致性为93.33%。
  • 治疗前队列KRAS/NRAS/BRAF/PIK3CA的PPA为100%、NPA为99.60%。

临床怎么用

  • Firefly可用于mCRC患者血浆cfDNA的KRAS/NRAS/BRAF/PIK3CA突变谱分析,作为组织检测的补充。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Evaluating the tumor RAS/BRAF status is important for treatment selection and prognosis assessment in metastatic colorectal cancer (mCRC) patients. Correction of artifacts from library preparation and sequencing is essential for accurately analyzing circulating tumor DNA (ctDNA) mutations. Here, we assessed the analytical and clinical performance of a novel amplicon-based next-generation sequencing (NGS) assay, Firefly™, which employs a concatemer-based error correction strategy. Methods Firefly assay targeting KRAS/NRAS/BRAF/PIK3CA was evaluated using cell-free DNA (cfDNA) reference standards and cfDNA samples from 184 mCRC patients. Plasma results were compared to the mutation status determined by ARMS-based PCR from matched tissue. Samples with a mutation abundance below the limit of detection (LOD) were retested again by droplet digital polymerase chain reaction (ddPCR) or NGS. Results The Firefly assay demonstrated superior sensitivity and specificity with a 98.89% detection rate at an allele frequency (AF) of 0.2% for 20 ng cfDNA. Generally, 40.76% and 48.37% of the patients were reported to be positive by NGS of plasma cfDNA and ARMS of FFPE tissue, respectively. The concordance rate between the two platforms was 80.11%. In the pre-treatment cohort, the concordance rate between plasma and tissue was 93.33%, based on the 17 common exons that Firefly™ and ARMS genotyped, and the positive percent agreement (PPA) and negative percent agreement (NPA) for KRAS/NRAS/BRAF/PIK3CA were 100% and 99.60%, respectively. Conclusions Total plasma cfDNA detected by Firefly offers a viable complement for mutation profiling in CRC patients, given the high agreement with matched tumor samples. Together, these data demonstrate that Firefly could be routinely applied for clinical applications in mCRC patients.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Wang B, Wu S, Huang F, et al. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients. Clin Chem Lab Med. 2019. PMID: 31339850. doi:10.1515/cclm-2019-0142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。